190 related articles for article (PubMed ID: 32586501)
1. Medical management of meningiomas.
Chukwueke UN; Wen PY
Handb Clin Neurol; 2020; 170():291-302. PubMed ID: 32586501
[TBL] [Abstract][Full Text] [Related]
2. Multiplatform profiling of meningioma provides molecular insight and prioritization of drug targets for rational clinical trial design.
Everson RG; Hashimoto Y; Freeman JL; Hodges TR; Huse J; Zhou S; Xiu J; Spetzler D; Sanai N; Kim L; Kesari S; Brenner A; De Monte F; Heimberger A; Raza SM
J Neurooncol; 2018 Sep; 139(2):469-478. PubMed ID: 29846894
[TBL] [Abstract][Full Text] [Related]
3. Non-NF2 mutations have a key effect on inhibitory immune checkpoints and tumor pathogenesis in skull base meningiomas.
Hao S; Huang G; Feng J; Li D; Wang K; Wang L; Wu Z; Wan H; Zhang L; Zhang J
J Neurooncol; 2019 Aug; 144(1):11-20. PubMed ID: 31177425
[TBL] [Abstract][Full Text] [Related]
4. First insight into the somatic mutation burden of neurofibromatosis type 2-associated grade I and grade II meningiomas: a case report comprehensive genomic study of two cranial meningiomas with vastly different clinical presentation.
Dewan R; Pemov A; Dutra AS; Pak ED; Edwards NA; Ray-Chaudhury A; Hansen NF; Chandrasekharappa SC; Mullikin JC; Asthagiri AR; ; Heiss JD; Stewart DR; Germanwala AV
BMC Cancer; 2017 Feb; 17(1):127. PubMed ID: 28193203
[TBL] [Abstract][Full Text] [Related]
5. Targeted drug therapy for meningiomas.
Norden AD; Drappatz J; Wen PY
Neurosurg Focus; 2007; 23(4):E12. PubMed ID: 17961036
[TBL] [Abstract][Full Text] [Related]
6. Inherited genetic syndromes and meningiomas.
Look A; Lonser RR
Handb Clin Neurol; 2020; 169():121-129. PubMed ID: 32553283
[TBL] [Abstract][Full Text] [Related]
7. YAP1-FAM118B Fusion Defines a Rare Subset of Childhood and Young Adulthood Meningiomas.
Schieffer KM; Agarwal V; LaHaye S; Miller KE; Koboldt DC; Lichtenberg T; Leraas K; Brennan P; Kelly BJ; Crist E; Rusin J; Finlay JL; Osorio DS; Sribnick EA; Leonard JR; Feldman A; Orr BA; Serrano J; Vasudevaraja V; Snuderl M; White P; Magrini V; Wilson RK; Mardis ER; Boué DR; Cottrell CE
Am J Surg Pathol; 2021 Mar; 45(3):329-340. PubMed ID: 33074854
[TBL] [Abstract][Full Text] [Related]
8. Meningioma genomics: a therapeutic challenge for clinicians.
Moussalem C; Massaad E; Minassian GB; Ftouni L; Bsat S; Houshiemy MNE; Alomari S; Sarieddine R; Kobeissy F; Omeis I
J Integr Neurosci; 2021 Jun; 20(2):463-469. PubMed ID: 34258948
[TBL] [Abstract][Full Text] [Related]
9. Clinical impact of targeted amplicon sequencing for meningioma as a practical clinical-sequencing system.
Yuzawa S; Nishihara H; Yamaguchi S; Mohri H; Wang L; Kimura T; Tsuda M; Tanino M; Kobayashi H; Terasaka S; Houkin K; Sato N; Tanaka S
Mod Pathol; 2016 Jul; 29(7):708-16. PubMed ID: 27102344
[TBL] [Abstract][Full Text] [Related]
10. Genetic landscape of meningioma.
Yuzawa S; Nishihara H; Tanaka S
Brain Tumor Pathol; 2016 Oct; 33(4):237-247. PubMed ID: 27624470
[TBL] [Abstract][Full Text] [Related]
11. SMO mutation status defines a distinct and frequent molecular subgroup in olfactory groove meningiomas.
Boetto J; Bielle F; Sanson M; Peyre M; Kalamarides M
Neuro Oncol; 2017 Mar; 19(3):345-351. PubMed ID: 28082415
[TBL] [Abstract][Full Text] [Related]
12. Novel Medical Therapies in Meningiomas.
Danish H; Brastianos P
Adv Exp Med Biol; 2023; 1416():213-223. PubMed ID: 37432630
[TBL] [Abstract][Full Text] [Related]
13. Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma.
Abedalthagafi M; Bi WL; Aizer AA; Merrill PH; Brewster R; Agarwalla PK; Listewnik ML; Dias-Santagata D; Thorner AR; Van Hummelen P; Brastianos PK; Reardon DA; Wen PY; Al-Mefty O; Ramkissoon SH; Folkerth RD; Ligon KL; Ligon AH; Alexander BM; Dunn IF; Beroukhim R; Santagata S
Neuro Oncol; 2016 May; 18(5):649-55. PubMed ID: 26826201
[TBL] [Abstract][Full Text] [Related]
14. Durable Control of Metastatic AKT1-Mutant WHO Grade 1 Meningothelial Meningioma by the AKT Inhibitor, AZD5363.
Weller M; Roth P; Sahm F; Burghardt I; Schuknecht B; Rushing EJ; Regli L; Lindemann JP; von Deimling A
J Natl Cancer Inst; 2017 Mar; 109(3):1-4. PubMed ID: 28376212
[TBL] [Abstract][Full Text] [Related]
15. Biology and clinical management challenges in meningioma.
Mawrin C; Chung C; Preusser M
Am Soc Clin Oncol Educ Book; 2015; ():e106-15. PubMed ID: 25993161
[TBL] [Abstract][Full Text] [Related]
16. EPH receptor signaling as a novel therapeutic target in NF2-deficient meningioma.
Angus SP; Oblinger JL; Stuhlmiller TJ; DeSouza PA; Beauchamp RL; Witt L; Chen X; Jordan JT; Gilbert TSK; Stemmer-Rachamimov A; Gusella JF; Plotkin SR; Haggarty SJ; Chang LS; Johnson GL; Ramesh V;
Neuro Oncol; 2018 Aug; 20(9):1185-1196. PubMed ID: 29982664
[TBL] [Abstract][Full Text] [Related]
17. Meningioma: current updates on genetics, classification, and mouse modeling.
Szulzewsky F; Thirimanne HN; Holland EC
Ups J Med Sci; 2024; 129():. PubMed ID: 38571886
[TBL] [Abstract][Full Text] [Related]
18. Molecular alterations in meningioma: prognostic and therapeutic perspectives.
Birzu C; Peyre M; Sahm F
Curr Opin Oncol; 2020 Nov; 32(6):613-622. PubMed ID: 32890025
[TBL] [Abstract][Full Text] [Related]
19. Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea.
Schrell UM; Rittig MG; Anders M; Koch UH; Marschalek R; Kiesewetter F; Fahlbusch R
J Neurosurg; 1997 May; 86(5):840-4. PubMed ID: 9126900
[TBL] [Abstract][Full Text] [Related]
20. Medical Management of Meningiomas: Current Status, Failed Treatments, and Promising Horizons.
Karsy M; Guan J; Cohen A; Colman H; Jensen RL
Neurosurg Clin N Am; 2016 Apr; 27(2):249-60. PubMed ID: 27012389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
